---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-086170"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2025-06-13T23:59:59+00:00"
generated_at: "2026-05-19T08:31:24.899440+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics appoints new director from Baker Bros.; shareholders approve increase in authorized shares

## Summary
- Appointed Paul Scherer, M.D. (Baker Bros. Advisors) as Class III director; granted options for 76,000 shares vesting over one year.
- Stockholders elected Martin Babler and Victor Sandor as Class II directors for three-year terms at 2025 annual meeting.
- Ratified Ernst & Young as independent auditor for fiscal year 2025 with 32,364,505 votes for, 132,459 against.
- Approved amendment increasing authorized non-voting common stock from 12,850,259 to 112,850,259 shares.

## SEC filing metadata
- accession: 0000950170-25-086170
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2025-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017025086170/0000950170-25-086170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017025086170/prld-20250611.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-086170
- JSON: https://secwatch.observer/filing/0000950170-25-086170.json
- Plain text: https://secwatch.observer/filing/0000950170-25-086170.txt

## Key facts
- Executive change
  Paul Scherer was appointed as Class III Director at Prelude Therapeutics Inc.
  - Action: appointed
  - Role: Class III Director
  source text: the Board appointed Paul Scherer, M.D., as a Class III director and as a member of the Compensation committee and the Governance Committee of the Board, effective as of the adjournment of the 2025 Annual Meeting of Stockholders (the “ Annual Meeting ”) on June 12, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000095017025086170/0000950170-25-086170-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.